secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2025-06-27T23:59:59+00:00
Accession:  0001193125-25-151276
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics 2025 annual meeting passes director elections, say-on-pay, auditor ratification
--------------------------------------------------------------------------------

- Class III directors Katina Dorton, Robert Gould, and Kate Haviland elected with 44.6M, 43.8M, and 33.2M votes for, respectively.
- Non-binding say-on-pay resolution approved with 46.1M votes for (99.8% of votes cast excluding broker non-votes).
- Stockholders selected one year as frequency of future say-on-pay votes (44.9M votes for one year).
- Ernst & Young LLP ratified as independent auditor for FY2025 with 49.5M votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312525151276/0001193125-25-151276-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312525151276/d916678d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-151276

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer